高瘤负荷转移性激素敏感性前列腺癌骨转移患者双联与三联治疗的比较:ARON-3研究结果
基于国际多中心ARON-3数据库,纳入841例高瘤负荷mHSPC骨转移患者,比较ADT+ARPI双联与ADT+ARPI+多西他赛三联治疗。在>10处骨转移患者中,调整后TTF差异有统计学意义(HR 0.49,95%CI 0.28-0.87;p=0.02),OS差异无统计学意义。结论需前瞻性验证。
要点
- 三联治疗在>10处骨转移患者中与更优的TTF相关(HR 0.49)。
- OS在>10处骨转移患者中数值上倾向三联但未达统计学显著(HR 0.48,p=0.1)。
- 双联治疗中ADT+阿比特龙中位OS为63.0个月,其余方案未达到。
核心结论
- 在高瘤负荷mHSPC骨转移患者中,TTF和OS估计值随骨转移负荷不同而变化,但正式交互检验未显示异质性证据。
- 这些发现需前瞻性验证。
研究设计与样本
- 基于国际多中心ARON-3数据库的回顾性研究,纳入841例接受双联(75%)或三联(25%)治疗的高瘤负荷mHSPC骨转移患者。
- 按骨转移数目(≤10 vs >10)分层,主要终点为TTF、PSA应答和OS。
主要发现
- 12周时,三联治疗与阿片类药物使用和ECOG体能状态变化相关。
- 中位OS:ADT+阿比特龙为63.0个月;ADT+阿帕他胺、ADT+恩扎卢胺和ADT+多西他赛+达罗他胺未达到。
- >10处骨转移患者中,调整后TTF组间差异有统计学意义(HR 0.49,95%CI 0.28-0.87;p=0.02)。
- >10处骨转移患者中,调整后OS差异数值上不同但无统计学意义(HR 0.48,95%CI 0.21-1.07;p=0.1)。
- 伴内脏转移患者中,TTF和OS估计值组间数值上不同但无统计学意义。
关键数值与推荐
- 高瘤负荷mHSPC定义依据CHAARTED分类。
- 骨转移负荷分层阈值为≤10 vs >10处。
- 双联治疗指ADT+ARPI,三联治疗指ADT+ARPI+多西他赛。
临床怎么用
- 对于高瘤负荷mHSPC伴>10处骨转移患者,三联治疗可能改善TTF,但OS获益未证实。
- 临床决策需结合骨转移负荷、体能状态及患者意愿个体化选择双联或三联方案。
局限性
- 探索性亚组分析,正式交互检验未显示异质性。
- 回顾性研究设计,结果需前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Data for direct comparison of the outcomes for androgen-deprivation therapy (ADT) + androgen signaling pathway-inhibitors (ARPI) versus ADT + ARPI + docetaxel are scant, especially in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC), according to CHAARTED classification and regarding to the number of bone metastases. DESIGN, SETTING AND PATICIPANTS: Relying on the multicentric international ARON-3 database, patients with high-volume mHSPC with bone metastases undergoing doublet versus triplet therapy were selected and stratified according to the number of bone metastases (≤10 vs >10). Primary endpoints consisted of time to treatment failure (TTF), prostate-specific antigen-response, and overall survival (OS). RESULTS AND LIMITATIONS: Overall, 841 patients treated with doublet (75%) or triplet (25%) therapy were included. At 12 wk, triplet therapy was associated with changes in opioid use and in Eastern Cooperative Oncology Group performance status. Median OS was 63.0 mo for ADT + abiraterone acetate and was not reached for ADT + apalutamide, ADT + enzalutamide, and ADT + docetaxel + darolutamide. Differences in adjusted TTF estimates between treatment groups were observed in patients with >10 bone metastases (hazard ratio [HR] 0.49, 95% confidence interval [CI] 0.28-0.87; p = 0.02), whereas adjusted OS estimates also differed numerically but were not statistically significant (HR 0.48, 95% CI 0.21-1.07; p = 0.1). In patients with concomitant visceral metastases, TTF and OS estimates also differed numerically by treatment group; however, these differences were not statistically significant. CONCLUSIONS: In exploratory subgroup analyses, TTF and OS estimates varied by bone metastatic burden, but formal interaction testing did not show evidence of heterogeneity. These findings require prospective validation.
引用
- Mandel PC, Wenzel M, Gandur Quiroga MN, et al. Doublet Versus Triplet Therapy in High-volume Metastatic Hormone-sensitive Prostate Cancer Patients with Bone Metastases: Results from the ARON-3 Study. Eur Urol Oncol. 2026. PMID: 42242941. doi:10.1016/j.euo.2026.05.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。